Drugs / BACTELIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04815798 | Jan 2022 → Aug 2023 | decubitus ulcer | Precisio Biotix Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BACTELIDE | “This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized...” NCT04815798 ↗ |
| Route | Topical | “This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.” NCT04815798 ↗ |